Radiopharm Theranostics
Business Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
L 3 62 Lygon St, Carlton, Victoria, 3053...Phone Number
+61398245254Revenue
<$5 MillionStock Symbol
RADIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical-stage biotechnology company developing innovative radiopharmaceuticals for precision oncology. Its pipeline combines targeted molecules with medical radioisotopes to create diagnostic and therapeutic products designed to improve cancer detection and treatment, addressing significant unmet needs in oncologyExplore more
Radiopharm Theranostics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Radiopharm Theranostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Radiopharm Theranostics had a recent Job posting/layoffs
Check if Radiopharm Theranostics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Radiopharm Theranostics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Radiopharm Theranostics launches new products
Earning: See what the market has to say on Radiopharm Theranostics recently announced quarterly report
Check out if Radiopharm Theranostics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Radiopharm Theranostics
Radiopharm Theranostics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Radiopharm Theranostics
Compare insights from companies similar to Radiopharm Theranostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Radiopharm Theranostics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Radiopharm Theranostics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Radiopharm Theranostics.
Radiopharm Theranostics financials insights
Gather financial insights about Radiopharm Theranostics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Private Equity
$70M
2026
Stock/Share Issuance
$8.8M
Radiopharm Theranostics Tech Stack
A closer look at the technologies used by Radiopharm Theranostics
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Clinical Operations
Funding
Funding
Person-Based
Compliance, Share Placement, Finance
Person-Based
Partnership, Pharmaceuticals, Clinical Operations
Radiopharm Theranostics News & Media
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company’s joint venture with MD Anderson Cancer Center Doses first patient at 70 mCi dose of RV-01, the first radiopharmaceutical therapeutic developed in Company’s joint venture with MD Anderson Cancer CenterRadiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpointRadiopharm Theranostics Reports Business Update
Reported positive results from the Phase 2b clinical trial of imaging agent RAD 101, showing 93% of evaluable patients treated with RAD 101 achieved the primary endpointRadiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
NEW YORK and SYDNEY, July 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announces that it has entered into a Securities Purchase Agreement (“SPA”) with certain U.S. accredited institutional investors to issue, in a registered direct offering, 1,281,646 American Depositary Share
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Radiopharm Theranostics
Sign Up For FreeTo access detailed company insights
Radiopharm Theranostics is a clinical-stage biotechnology company developing innovative radiopharmaceuticals for precision oncology. Its pipeline combines targeted molecules with medical radioisotopes to create diagnostic and therapeutic products designed to improve cancer detection and treatment, addressing significant unmet needs in oncology... Read More
